Drug Profile
Tasimelteon - Vanda Pharmaceuticals
Alternative Names: BMS-214778; HETLIOZ; HETLIOZLQ; VEC-162Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Vanda Pharmaceuticals
- Class Amides; Antidepressants; Behavioural disorder therapies; Benzofurans; Cyclopropanes; Sleep disorder therapies; Small molecules
- Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Circadian rhythm sleep disorders
- Phase III Pervasive child development disorders
- Discontinued Major depressive disorder
Most Recent Events
- 05 Feb 2024 FDA assigns PDUFA action date of 04/03/2024 for sNDA of Tasimelteon for Circadian rhythm sleep disorders (Jet lag disorder)
- 31 Dec 2023 Vanda pharmaceuticals has patent protection for tasimelteon in USA
- 27 Jul 2023 Vanda disagrees with the Federal Circuit's ruling and requested a rehearing from the Federal Circuit